dry eye disease
Ophthalmology · 2021–2022
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ciclosporin Treatment of chronic severe dry eye disease with keratitis in patients with corneal fluorescein staining grade 4 and ocular surface disease index score ≥23,… | Mar 2022 | Recommended with restriction | none received |
| ciclosporin Treatment of patients with severe keratitis with dry eye disease (DED) who have failed to achieve adequate symptom control with preservative-free tear… | Mar 2021 | Recommended with restriction | input received Optometry Australia |
Who spoke
Optometry Australia
What the PBS pays
$10M in government benefit over 2024–25, across 82,958 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ciclosporin | $9.9M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| ciclosporinCiclosporin for treating dry eye disease that has not improved despite treatment with artificial tears | TA369 | recommended | 2015-12 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| lifitegrastXIIDRA lifitegrast 50 mg/mL eye drops single-use ampoules | 2019 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.